3-Aminopyrrolidinone Farnesyltransferase Inhibitors:  Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

Ian M. Bell(United States Military Academy), C. Blair Zartman(United States Military Academy), David Heimbrook(United States Military Academy), Robert B. Lobell(United States Military Academy), Marc Abrams(Dicerna Pharmaceuticals (United States)), Nancy E. Kohl(United States Military Academy), George D. Hartman(Joint BioEnergy Institute), Samuel Graham(Georgia Institute of Technology), Joseph Culberson(United States Military Academy), Kelly Hamilton(United States Military Academy), W. Wayt Gibbs(United States Military Academy), Joel R. Huff(United States Military Academy), Carl F. Homnick(United States Military Academy), Eileen S. Walsh(Janssen (Switzerland)), Hema Bhimnathwala(United States Military Academy), L.S. Beese(Duke University), Joseph J. Lynch(United States Military Academy), Jeffrey S. Taylor(United States Military Academy), Michael J. Bogusky(United States Military Academy), Carolyn A. Buser(United States Military Academy), Kelem Kassahun(United States Military Academy), Kenneth S. Koblan(Sumitomo Dainippon Pharma (United States)), Douglas C. Beshore(United States Military Academy), Steven N. Gallicchio(United States Military Academy), Joseph P. Davide(United States Military Academy), Theresa M. Williams(United States Military Academy), A. David Rodrigues(Bristol-Myers Squibb (Germany)), R. Robinson(United States Military Academy), Hans E. Huber(Health Strat (Kenya)), Christine Fernandes(United States Military Academy), Michelle Ellis-Hutchings(United States Military Academy)
Journal of Medicinal Chemistry
May 3, 2002
Cited by 86


Related Papers